This Company is set to Transform the Nuclear Medicine Market with its Theragnostic Approach

Advanced Accelerator Applications (AAA), headquartered in France has introduced an innovative theragnostic approach along with molecular nuclear medicine. Stefano Buono, Chief Executive Officer of the company told The Pharma Letter that the company is a leader in European market in the production & commercialization of molecular nuclear diagnostic radiopharmaceuticals for single-photon emission computed tomography (SPECT) and positive emission tomography (PET). The company is also set to make new its presence felt in new regions with its unique strategy of combining diagnostics and therapeutics.

Big pharma would have an eye on theragnostic approach of AAA to neuroendocrine tumors (NETs) and treatment of such tumors with the help of its therapeutic, Lutathera (Lutetium Lu 177 dotatate). Lutathera is in orphan status and under review, by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). The company’s road to become a drug developer would be unconventional as Lutathera reaches the market.

AAA has not yet planned for partnerships or agreements on Lutathera; but it may opt for it in the future. The next line of drugs it plans to bring in the market are 177Lu-PSMA-R2 and complementary diagnostic 68Ga-PSMA-R2. These drugs address prostate cancer, which would enable them to have a huge patient group. This approach is already giving promising results in Germany. “German laws allow sometimes faster access to novel technologies in the field of nuclear medicine, and so there has been an uptake of the diagnostic examination,” Mr. Buono said. “I believe many thousands of patients have been already diagnosed using a PSMA-guided compound.”

Enquire about report @ http://bit.ly/2reGmDS

Mr. Buono, CEO and a physicist by background, set up AAA in 2002 to develop a patent in the radioisotope production field from the European Organization for Nuclear Research (CERN). “This opportunity gave me the possibility to understand the nuclear medicine market and at that time a new modality of imaging was explored – that was PET,” he said. “The drug for that modality, that had to be injected into patients for the imaging, was complicated to manufacture. You needed a particle accelerator, and they had only a 10 hour shelf-life, so it needed a completely new model.”

Mr. Buono accepted the challenge to produce an industrial model for those drugs in the European region. There were only few companies in France at that time and remaining companies were operating for only academic manufacturing and use. The company’s model proved to be successful and AAA became the leader in the European molecular nuclear medicine industry. It has produced and commercialized eight diagnostic PET and SPECT products for indications in neurology, cardiology, clinical oncology, and inflammatory/infectious diseases. The company also has third-party producer and distributor agreements with the leading U.S. pharmaceutical companies such as Eli Lilly and GE Healthcare.

In its recent report on the EMEA (Europe, Middle East, and Africa) Nuclear Medicine & Radio Pharmaceuticals Market, Big Market Research offers an extensive analysis of leading manufacturers, key segments, and potential opportunities. Moreover, the research also offers insights on sales, revenue, growth rate, and market share for the period, 2012–2022. The report is helpful for leading market players, investors, shareholders, and new entrants to weigh up opportunities and make future-oriented decisions.

Request sample report @ http://bit.ly/2s8Vd2o

About Company :
Big Market Research uniqueness lies in its highly ethical reports at economical rates because we value your relationship and growth more than money. Your growth is our aim. With the arsenal of different search reports, we help you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

Contact Us :
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
Direct : +1-971-202-1575
Toll Free : + 1-800-910-6452
Email: [email protected]
Web: https://www.bigmarketresearch.com